Vogenx, Inc. Net Income
Vogenx, Inc. (VOGX) reported Net Income of -$384.43 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-09-17.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-09-17
- Vogenx, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$384.43K.
- Vogenx, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$475.45K.
- Vogenx, Inc. net income (loss) attributable to parent for the quarter ending 2025-06-30 was -$294.80K.
- Vogenx, Inc. net income (loss) attributable to parent for the quarter ending 2025-03-31 was -$356.62K.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month |
|---|---|---|
| 2026-06-30 | -$384.43K 10-Q · filed 2026-09-17 | -$859.88K 10-Q · filed 2026-09-17 |
| 2026-03-31 | -$475.45K 10-Q · filed 2026-09-17 | |
| 2025-06-30 | -$294.80K 10-Q · filed 2026-09-17 | -$651.42K 10-Q · filed 2026-09-17 |
| 2025-03-31 | -$356.62K 10-Q · filed 2026-09-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |